Save the Date for the Second Annual Boston Society Medical Symposium on Acute Myeloid Leukemia (AML)
October 4, 2019

Broad Institute of MIT and Harvard 
415 Main Street 
Cambridge, MA 02142

More Details Soon!



Download a copy of the 2018 conference program:

AML 2018 Program Guide


2018 Plenary Speaker


Gwen Nichols, MD, Chief Medical Officer, The Leuklemia & Lymphoma Society

Can AML Precision Science Become AML Precision Clinical Reality?



Invited Speakers 


Naval G. Daver, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Immune Checkpoint and Vaccine Approaches in AML



Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

FDA Work to Expedite the Development of Products to Address Serious and Life-Threatening Conditions


Andrew M. Brunner MD, Center for Leukemia, Massachusetts General Hospital

State of the Clinic: Treating AML in 2018


Bikash Verma, MD, DVM, Head, Clinical Development & Medical Affairs, Celyad

Novel CAR-T Therapy for AML 



John F. DiPersio, MD, PhD, Virginia E and Samuel J Golman Professor, Chief, Division of Oncology, Deputy Director, Siteman Cancer Center, Washington University School of Medicine

Novel Targeting of AML and T-ALL


Patrick Zweidler-McKay, MD, PhD, Medical Director for Hematologic Malignancies, ImmunoGen

ADCs in AML: GO and Beyond


Terry J. Fry, MD, Investigator, Pediatric Oncology Branch, Head, Hematologic Malignancies Section, Center for Cancer Research, National Cancer Institute

Immunotherapeutic Approaches for AML


Yi-Bin Albert Chen, MD, Program Director, Blood & Marrow Transplant (BMT) Program at the MGH Cancer Center

AML after Transplant: Are We Becoming High Maintenance?


Coleman Lindsley, MD, PhD, Assistant Professor, Harvard Medical School, Dana-Farber Cancer Institute

genomics of myeloid malignancies -Title TBA


Karin Gaensler, MD, Clinical Professor of Medicine, UCSF

TriLeukeVax: A "Next Generation" Autologous Immunotherapy for Leukemia



AML 2018 Sessions 

Session I:  The Current Landscape

Session II:  State of the Art Research and Treatment Options

Session III:  On the Horizon





 Join our Linkedin Group:


Session I:  The Current Landscape

Session II:  State of the Art Research and Treatment Options

Session III:  On the Horizon


Click here to register for the AML 2018 conference online.

AML 2018 will take place

March 15, 2018

Broad Institute

Cambridge, MA


The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3


Sign Up Today!

Privacy Policy